Articles

Ebola Outbreak's Impact on Women and Girls: A Call to Action

The ongoing Ebola outbreak poses significant risks to women and girls, potentially leading to increased violence. This article examines the implications for the pharmaceutical industry.

Reforming PEPFAR: Insights from Former CDC Directors

Eight former CDC directors advocate for reforming PEPFAR rather than dismantling it, highlighting critical implications for the pharmaceutical sector.

Measuring What Matters: New Priorities in COA Selection

This article delves into the new priorities in Clinical Outcome Assessment (COA) selection, highlighting their significance for pharmaceutical teams and stakeholders.

FDA Grants Early Access to Promising Drug for Pancreatic Cancer

The FDA has granted early access to a promising new drug for pancreatic cancer, marking a significant milestone in oncology. This analysis explores the implications for investors and pharma teams.

Unlocking Real-World Evidence in the AI Era

This article delves into the significance of real-world evidence in the AI era, highlighting its implications for pharmaceutical teams and decision-makers.

Process Intensification: Separating Fact from Fiction in Pharma

This article delves into the truths and misconceptions surrounding process intensification in the pharmaceutical sector, highlighting its significance for business development teams.

Get Ready for APPOS Hartford 2026: Key Insights and Expectations

APPOS Hartford 2026 is set to be a pivotal event for B2B stakeholders in the pharma industry. With key data readouts and company presentations, this event promises valuable insights.

Eli Lilly and Verve's Gene Editor: A Breakthrough in Cholesterol Management

Eli Lilly announces promising results from Verve’s gene editing study, potentially transforming cholesterol treatment. Explore the implications for the pharmaceutical industry.

FDA Approves Expanded Access for Daraxonrasib in Pancreatic Cancer

The FDA has approved expanded access for Daraxonrasib in pancreatic cancer, presenting new opportunities for patients and investors alike. This article explores the implications of this approval for the pharmaceutical landscape.

The Perimenopause Movement: A Double-Edged Sword for Women

This article examines the perimenopause movement's impact on women's health and its implications for the pharmaceutical industry.

Biogen and Denali's Parkinson's Drug Trial: What Went Wrong?

Biogen and Denali's recent trial for a Parkinson's drug has not met expectations, raising questions about future strategies and investments in this space.

Designing a Future-Ready Tech Roadmap for Emerging Pharma

This article delves into the essential strategies for creating a tech roadmap that empowers emerging pharmaceutical companies to thrive in a rapidly evolving landscape.

Medicaid Funding Cuts: Implications for Pharma Providers

This article examines the recent cuts to Medicaid funding and their implications for pharmaceutical providers, focusing on the potential future under the Trump administration.

FDA Approval for Datroway: Implications for Breast Cancer Treatment

The FDA has granted approval for Datroway, a significant development for breast cancer treatment by Daiichi Sankyo and AstraZeneca. This article explores the implications for investors and pharma teams.

AstraZeneca and Daiichi Secure FDA Approval for Datroway in TNBC

AstraZeneca and Daiichi have gained FDA approval for Datroway as a first-line treatment for TNBC, surpassing Gilead. This article explores the implications for the pharmaceutical landscape.

GOP Lawmaker Urges Action on China Biotech Deals

A GOP lawmaker has called for the Trump administration to take action against Chinese biotech investments. This article explores the potential impacts on the pharmaceutical sector.

Utah's AI Prescribing Experiment: Progress and Insights

This article delves into the current status of Utah's AI prescribing experiment, highlighting key insights and implications for the pharmaceutical sector.

FDA Approves Gilead's Hepatitis D Drug: Implications for Pharma

The FDA has cleared Gilead's hepatitis D drug after a four-year wait, marking a significant milestone in hepatitis treatment. This article explores the implications for the pharmaceutical landscape.

Palvella Secures $230M to Advance QTORIN for Rare Diseases

Palvella Therapeutics has raised $230 million to support the NDA for QTORIN, targeting rare diseases. This funding positions the company for significant growth.

ASCO26: Key Data Insights Ahead of the Major Cancer Drug Meeting

As ASCO26 approaches, we delve into five critical data snapshots that will shape the future of cancer drug development. This article provides insights for pharma teams and investors.